Afleveringen
-
In this episode of Digital Health Inside Out, we sit down with Amit Phull, MD, Chief Clinical Experience Officer at Doximity, to discuss the next era of clinical AI, physician workflows, and what it really takes to build technology that doctors can trust.Amit shares his journey from emergency medicine and computer science to joining Doximity in its early days, how the company evolved from “LinkedIn for doctors” into a clinical workflow platform, and why user feedback from physicians remains central to Doximity’s product strategy.We discuss Doximity’s Clinical AI Suite, Doximity Ask, the acquisition of Pathway, the role of knowledge graphs and retrieval in clinical AI, and the company’s Peer Check initiative, where thousands of physicians review AI-generated clinical answers. Amit also explains why trust, accuracy, and reliability are still the biggest barriers to AI adoption in healthcare.The conversation also covers telemedicine, ambient documentation, physician burnout, pharma advertising, enterprise healthcare partnerships, competition in clinical AI, and the ongoing debate around general-purpose AI models versus specialized healthcare AI tools.If you are building, investing in, or adopting healthcare AI, this interview offers a rare inside look at how one of the largest physician networks in the U.S. is approaching AI in medicine.Topics covered:
Doximity’s evolution and “eras”Clinical AI Suite and Doximity AskPeer Check and physician-reviewed AI answersPathway’s clinical knowledge graphAI trust, accuracy, and reliability in healthcarePhysician burnout and administrative burdenTelemedicine and clinical workflow toolsCompetition in clinical AIThe future of AI in healthcareGuest:Amit Phull — Chief Clinical Experience Officer at Doximityhttps://www.linkedin.com/in/amit-phull-09931667/Co-Host:Alex Koshykov — CEO @ YODD, COO @ BeKey.io https://www.linkedin.com/in/alex-koshykov/Co-Host:Sergei Polevikov @sergeiAI — Founder of AI Health Uncuthttps://www.linkedin.com/in/sergeiai/
-
In this episode of Digital Health Vitals, we break down the biggest digital health and healthcare AI stories from June — including a new Nature Medicine paper on general-purpose LLMs outperforming specialized clinical AI tools, OpenEvidence’s controversial response, UnitedHealth’s $3B AI investment, Midjourney Medical’s ultrasonic body scanner concept, and Abridge’s new AI-native clinician intelligence platform.This episode features Alex Koshykov, Sergei Polevikov, Stephanie Davis, and special guest Amit Phull — emergency medicine physician, clinical assistant professor at GW, and Chief Clinical Experience Officer at Doximity.
-
Zijn er afleveringen die ontbreken?
-
In this live episode of Digital Health Vitals, recorded during our Health2Tech Tech Week event in New York, we bring our monthly digital health news discussion to the stage. We break down what is happening across healthcare AI, digital health startups, health tech investing, public markets, direct-to-consumer healthcare, AI health companions, care navigation, and administrative automation.
-
In this episode of Digital Health Inside Out, Alex Koshykov and Sergei Polevikov sit down with Piotr Orzechowski, founder and CEO of Infermedica, one of the most established companies in AI-powered symptom assessment and clinical triage.We discuss how the symptom-checker category has changed, why standalone consumer symptom checkers may be “dead,” and why clinical-grade AI triage is still becoming more important within real healthcare workflows.Piotr shares the story of building Infermedica from Poland into a global healthtech company, the challenges of selling medical AI internationally, how Infermedica competes in the age of ChatGPT and LLMs, and why medical device certification, physician validation, liability, and evidence still matter.We also cover AI accuracy claims, peer-reviewed validation, neurosymbolic AI, voice-based triage, fundraising for founders from Eastern Europe, the future of AI diagnosis, and what kind of companies might eventually acquire Infermedica.If you care about healthcare AI, digital health, symptom checkers, clinical triage, LLMs in medicine, or the future of regulated medical AI, this conversation is for you.
-
GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound have become one of the biggest stories in healthcare, obesity medicine, pharma, telehealth, and even culture.But are GLP-1s truly transforming obesity care — or are we outsourcing willpower to pharma?In this episode of Digital Health Inside Out, Alex Koshykov and Sergey Polevikov sit down with Dr. Beverly Chang, Dave Knapp, and Sean Sullivan to unpack the science, business, safety concerns, access issues, and social debate around GLP-1 medications.
-
In this episode of Digital Health Vitals, we break down the biggest stories shaping digital health, healthcare AI, health tech investing, payer strategy, value-based care, and digital health startup funding in 2026. If you’re interested in AI in healthcare, digital health funding, healthcare startups, value-based care, payer-provider dynamics, clinical AI, healthcare public markets, or health tech business models, this episode is for you.
-
What happens when one of digital health’s sharpest observers sits down to talk about AI hype, health tech media, IPOs, storytelling, and the future of the industry?In this episode of Digital Health Inside Out, we speak with Christina Farr, a former CNBC reporter, CEO of Second Opinion, and GP at Scrub Capital, advisor, podcaster, and one of the most thoughtful voices in healthcare innovation.We talked about Christina’s transition from journalism into venture and media, whether she could have had a bigger impact by staying in reporting, the problem with how healthcare AI talks about job loss, why most companies still tell bad stories, what founders should share more openly, whether the digital health IPO window is really reopening, why Big Tech keeps struggling in healthcare, and whether AI scribes are a real breakthrough or just the latest wave of hype.This was an honest, nuanced, and at times uncomfortable conversation — exactly the kind we like to have on this channel.If you enjoy candid conversations about digital health, healthcare AI, startups, venture capital, and the realities behind the headlines, subscribe to the channel.
-
In this episode of Digital Health Interviews, we sit down with Shiv Rao, CEO and co-founder of Abridge, to talk about the real future of ambient AI in healthcare. We also get into some of the harder questions: valuation hype, investor influence, FDA regulation, liability, Epic’s role in the market, and what healthcare may look like as AI becomes more deeply embedded into clinical workflows.
-
In Digital Health Vitals, Episode 5, we break down the biggest digital health news shaping 2026 — from major investments and acquisitions to the growing race for AI-powered healthcare platforms. If you’re a founder, investor, operator, or clinician trying to understand where digital health and AI in healthcare are heading, this episode will give you a clear, practical perspective.
-
In Digital Health Vitals, Episode 4, we break down the most important and controversial developments shaping digital health, AI in healthcare, and the business of care delivery — from startup bankruptcies to AI scribes and the monetization of clinical evidence driving the healthcare innovation ecosystem right now.
-
A grounded discussion on longevity, separating real science from marketing hype as the field goes mainstream.
We explore what changed in recent years, key longevity metrics, the influencer effect, and where attention truly belongs—from lifestyle fundamentals to supplements and GLP-1 drugs. -
A clear-eyed discussion on Generative AI in healthcare, separating real clinical impact from hype.
We break down where AI truly improves patient care and diagnostics—and where the promises fall short.
-
A sharp debate on whether VC culture has harmed digital health, unpacking how aggressive investment tactics shape innovation, sustainability, and exits.
We explore the future of digital health funding and whether AI can help founders rely less on venture capital.
